Company profile for Forma Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high u...
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. We aim to create futures for patients, their families and our employees.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
300 North Beacon Street, Suite 501 Watertown, MA 02472
Telephone
Telephone
617.679.1970
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://endpts.com/novo-nordisk-offloads-preclinical-cancer-candidate-from-1-1b-forma-buyout-debiopharm/

Amber Tong ENDPTS
02 Mar 2023
Rigel wins US approval of rival drug to Servier leukemia treatment
Rigel wins US approval of rival drug to Servier leukemia treatment

03 Dec 2022

// Christopher Newman BIOPHARMADIVE

https://www.biopharmadive.com/news/rigel-pharmaceuticals-leukemia-rezlidhia-fda-approval/637843/

Christopher Newman BIOPHARMADIVE
03 Dec 2022

https://www.globenewswire.com/news-release/2022/10/14/2534660/0/en/Novo-Nordisk-announces-the-completion-of-the-Forma-Therapeutics-acquisition.html

GLOBENEWSWIRE
14 Oct 2022

https://ir.formatherapeutics.com/news-releases/news-release-details/novo-nordisk-acquire-forma-therapeutics-and-expand-presence

PRESS RELEASE
01 Sep 2022

https://www.businesswire.com/news/home/20220805005036/en

BUSINESSWIRE
05 Aug 2022

https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-and-forma-therapeutics-announce-licensing-agreement-for-olutasidenib-a-novel-mutant-idh1-inhibitor-for-the-potential-treatment-of-relapsed-or-refractory-acute-myeloid-leukemia-301598297.html

PRNEWSWIRE
02 Aug 2022

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty